Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

Post published:June 21, 2022
Post category:Press Release

Dr. John H. Krystal, world-leading expert in alcoholism and depression, will serve on scientific advisory board

Source link

Tags: Clearmind Medicine

Leave a Reply Cancel reply

Real-World Data Reveals Variability in Access to, and Use of, SpravatoSeptember 13, 2024
While Janssen’s Spravato is on-track to become a blockbuster drug, access to the esketamine nasal spray product continues to be a key Acchiles heel for patients and their providers. Here, through study of two recent publications and interviews with their authors, we look at variability in access to, and real-world usage of, the therapy that psychedelic drug developers are increasingly hoping to imitate.
Pα+ Psychedelic Bulletin #172: Lykos Scales Back IIT Program, CEO Steps Down; Psyence Scoops Up Clairvoyant for Peanuts; Mindstate’s Moxy Enters Phase ISeptember 9, 2024
Lykos Scales Back Investigator-Initiated Trials Program, Refers Some Researchers to PharmAla • Lykos Appoints ‘Pharma Veterans’ to C-Suite • Psyence Scoops Up Clairvoyant for Peanuts • Mindstate’s Moxy Enters Phase I Trial • Embattled Braxia Bought for $180k • UK Gov. Unveils £400m Plan to Catalyse Clinical Trials • GH Research Waiting on Tox Studies to Respond to FDA’s Clinical Hold • Cydex Sues Bexson Over Psychedelic Salt Patents • and more...
Exclusive: David Hough on Lykos’ Path to ResubmissionSeptember 4, 2024
Josh sits down with the man drafted in by Lykos to plot a path to resubmitting its MDMA application. They talk about Hough’s experience in developing Spravato to eventual approval and how that might inform any future clinical development of MDMA, Hough’s thoughts about the FDA’s verdict and the AdComm that preceded it, what a future Phase 3 program might look like, and more…
Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to Handle Functional Unblinding; Doblin Charts a Future for MAPS; DEA Plots Ketamine CrackdownAugust 30, 2024
Lykos CEO Provides AdComm Feedback to FDA Commissioner • Cybin Plans to Fight Functional Unblinding with ‘Firewall’ • Doblin Charts a Future for MAPS • DEA Plots Ketamine Crackdown • Colorado Closes First Round of Rulemaking for State Psychedelics Program • and more...
What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2)August 28, 2024
In the second of a two-part series, we look at key trial design features FDA is expected to require of any future Phase 3 study from Lykos. Here, we run through how the MDMA drug developer will be expected to account for euphoria and other ‘positive’ adverse events, address selection bias, and favour larger academic and medical facilities as trial sites over private practices. What’s more, the company might be expected to outsource much of the trial's day-to-day operations.

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

Leave a Reply Cancel reply

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

You Might Also Like

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

Mind Medicine MindMed : MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

Sep 13, 2022, 16:50 ET MINDCURE Announces Financial Results for Fiscal 2022 VANCOUVER, BC, Sept. 13, 2022 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") today announced its financial results for the three and twelve months…

Leave a Reply Cancel reply

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights